Evidence map›Paper›PMID 35456784›Full record

ArticleMicroorganisms2022

Effect of Combination Antibiotic Empirical Therapy on Mortality in Neutropenic Cancer Patients with

Adaia Albasanz-Puig, Xavier Durà-Miralles, Júlia Laporte-Amargós, Alberto Mussetti, Isabel Ruiz-Camps, Pedro Puerta-Alcalde, Edson Abdala, Chiara Oltolini, Murat Akova, José Miguel Montejo and 32 more

Open access · goldAbstract read
In one paragraph

Article in Microorganisms, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.4field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 13 citations in OpenAlex.

  1. Genomic diversity ofMicrobial genomics · 2026
    Article
  2. Review
  3. Article
  4. Review
  5. Microorganisms · 2024
    Article
  6. Article
  7. Antimicrobial Treatment ofAntibiotics (Basel, Switzerland) · 2022
    Review
  8. Pathogens (Basel, Switzerland) · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

42 authors at 20 institutions in 11 countries.

Adaia Albasanz-PuigInfectious Diseases Department, Bellvitge University Hospital, IDIBELL, University of Barcelona, 08907 Barcelona, Spain.
Xavier Durà-MirallesInfectious Diseases Department, Bellvitge University Hospital, IDIBELL, University of Barcelona, 08907 Barcelona, Spain.
Júlia Laporte-AmargósInfectious Diseases Department, Bellvitge University Hospital, IDIBELL, University of Barcelona, 08907 Barcelona, Spain.
Alberto MussettiHematology Department, Catalan Institute of Oncology (ICO)-Duran i Reynals Hospital, IDIBELL, 08907 Barcelona, Spain.ORCID 0000-0002-4088-036X
Isabel Ruiz-CampsCentro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, 28029 Madrid, Spain.
Pedro Puerta-AlcaldeInfectious Diseases Department, Hospital Clínic i Provincial, 08035 Barcelona, Spain.
Edson AbdalaInstituto do Câncer do Estado de São Paulo, Faculty of Medicine, University of São Paulo, Sao Paulo 01246, Brazil.
Chiara OltoliniUnit of Infectious and Tropical Diseases, IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy.
Murat AkovaDepartment of Infectious Diseases, Hacettepe University School of Medicine, 06230 Ankara, Turkey.ORCID 0000-0002-6904-9473
José Miguel MontejoInfectious Diseases Department, Cruces University Hospital, 48903 Bilbao, Spain.
Malgorzata MikulskaDivision of Infectious Diseases, Department of Health Sciences, University of Genoa (DISSAL) and Ospedale Policlinico San Martino, 16132 Genoa, Italy.ORCID 0000-0002-5535-4602
Pilar Martín-DávilaCentro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, 28029 Madrid, Spain.
Fabián HerreraInfectious Diseases Section, Department of Medicine, Centro de Educación Médica e Investigaciones Clínicas (CEMIC), Buenos Aires C1430EFA, Argentina.
Oriol GaschInfectious Diseases Department, Parc Taulí University Hospital, Sabadell, 08208 Barcelona, Spain.
Lubos DrgonaOncohematology Department, Comenius University and National Cancer Institute, 81499 Bratislava, Slovakia.
Hugo Manuel Paz MoralesInfectious Diseases Department, Hospital Erasto Gaertner, Curitiba 81520-060, Brazil.
Anne-Sophie BrunelInfectious Diseases Department, Department of Medicine, Lausanne University Hospital, Centre Hospitalier Universitaire Vaudois (CHUV), 1011 Lausanne, Switzerland.ORCID 0000-0001-9437-1977
Estefanía GarcíaHaematology Department, Reina Sofía University Hospital-IMIBIC-UCO, 14004 Córdoba, Spain.
Burcu IslerDepartment of Infectious Diseases and Clinical Microbiology, Istanbul Education and Research Hospital, Istanbul 34668, Turkey.
Winfried V KernDivision of Infectious Diseases, Department of Medicine II, University of Freiburg Medical Center and Faculty of Medicine, 79110 Freiburg, Germany.
Pilar Retamar-GentilCentro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, 28029 Madrid, Spain.
José María AguadoCentro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, 28029 Madrid, Spain.ORCID 0000-0002-9520-8255
Milagros MonteroInfectious Diseases Service, Hospital del Mar, Infectious Pathology and Antimicrobials Research Group (IPAR), Institut Hospital del Mar d'Investigations Mèdiques (IMIM), Universitat Autònoma de Barcelona (UAB), CEXS-Universitat Pompeu Fabra, 08003 Barcelona, Spain.
Souha S KanjInfectious Diseases Division, American University of Beirut Medical Center, Beirut 110236, Lebanon.
Oguz R SipahiFaculty of Medicine, Ege University, Izmir 35040, Turkey.
Sebnem CalikDepartment of Infectious Diseases and Clinical Microbiology, University of Health Science Izmir Bozyaka Training and Research Hospital, Izmir 35170, Turkey.
Ignacio Márquez-GómezInfectious Diseases Department, Hospital Regional de Málaga, 29010 Málaga, Spain.ORCID 0000-0002-9555-5767
Jorge I MarinInfectious Diseases and Clinical Microbiology Department, Clínica Maraya, Pereira, Colombia, Critical Care and Clinical Microbiology Department, Manizales 170001-17, Colombia.
Marisa Z R GomesHospital Federal dos Servidores do Estado, Instituto Oswaldo Cruz, Fundação Oswaldo Cruz, Ministério da Saúde, Rio de Janeiro 20221-161, Brazil.ORCID 0000-0001-6492-1034
Philipp HemmatiDepartment of Hematology, Oncology and Palliative Care, Klinikum Ernst von Bergmann, Academic Teaching Hospital of Charité University Medical School, 10117 Berlin, Germany.
Rafael AraosFacultad de Medicina Clínica, Instituto de Ciencias e Innovación en Medicina, Alemana Universidad del Desarrollo, Santiago de Chile, and Millennium Initiative for Collaborative Research on Bacterial Resistance (MICROB-R), Santiago de Chile 12461, Chile.
Maddalena PeghinInfectious Diseases Clinic, Department of Medicine, University of Udine and Azienda Sanitaria Universitaria Integrata, 33100 Udine, Italy.ORCID 0000-0002-4640-679X
José Luis Del PozoInfectious Diseases and Microbiology Unit, Faculty of Medicine, Navarra University Clinic, 31008 Pamplona, Spain.ORCID 0000-0002-5402-3334
Lucrecia YáñezHaematology Department, Marqués de Valdecilla University Hospital, 39008 Santander, Spain.
Robert TilleyMicrobiology Department, University Hospitals Plymouth NHS Trust, Plymouth 8DH, UK.
Adriana ManzurInfectious Diseases, Hospital Rawson, San Juan J5400, Argentina.
Andres NovoHaematology Department, Son Espases University Hospital, 07120 Palma de Mallorca, Spain.
Natàlia PallarèsStatistics Advisory Service, Institute of Biomedical Research of Bellvitge, Rovira i Virgili University, 08908 Tarragona, Spain.
Alba BergasInfectious Diseases Department, Bellvitge University Hospital, IDIBELL, University of Barcelona, 08907 Barcelona, Spain.ORCID 0000-0002-5434-7670
Jordi CarratalàInfectious Diseases Department, Bellvitge University Hospital, IDIBELL, University of Barcelona, 08907 Barcelona, Spain.
Carlota GudiolInfectious Diseases Department, Bellvitge University Hospital, IDIBELL, University of Barcelona, 08907 Barcelona, Spain.ORCID 0000-0003-3095-4422
On Behalf Of The Ironic Study Group
Instituto de Salud Carlos III · ESBellvitge University Hospital · ESAmerican University of Beirut Medical Center · LBCentro de Educación Médica e Investigaciones Clínicas Norberto Quirno · ARClinica Universidad de Navarra · ESComenius University Bratislava · SKDeleted InstitutionEge University · TRHacettepe University · TRHospital Clínic de Barcelona · ESHospital de Cruces · ESHospital Erasto Gaertner · BRHospital Federal dos Servidores do Estado · BRHospital Regional Universitario de Málaga · ESHospital Universitario Son Espases · ESInstitut d'Investigació Biomédica de Bellvitge · ESInstituto Cajal · ESInstituto Maimónides de Investigación Biomédica de Córdoba · ESIzmir University · TRKlinikum Ernst von Bergmann · DE

Funding

Instituto de Salud Carlos III CB21/13/00009, CB21/13/00079, CB21/13/00054, CB21/13/00086, CB21/13/00012
6 · The paper itself

Abstract

To assess the effect of combination antibiotic empirical therapy on 30-day case-fatality rate in neutropenic cancer patients with Pseudomonas aeruginosa (PA) bacteremic pneumonia. This was a multinational, retrospective cohort study of neutropenic onco-hematological patients with PA bloodstream infection (BSI) (2006−2018). The effect of appropriate empirical combination therapy, appropriate monotherapy and inappropriate empirical antibiotic therapy [IEAT] on 30-day case-fatality was assessed only in patients with PA bacteremic pneumonia. Among 1017 PA BSI episodes, pneumonia was the source of BSI in 294 (28.9%). Among those, 52 (17.7%) were caused by a multidrug-resistant (MDR) strain and 68 (23.1%) received IEAT, mainly when the infection was caused by an MDR strain [38/52 (73.1%) vs. 30/242 (12.4%); p < 0.001]. The 30-day case-fatality rate was higher in patients with PA bacteremic pneumonia than in those with PA BSI from other sources (55.1% vs. 31.4%; p < 0.001). IEAT was associated with increased 30-day case-fatality (aHR 1.44 [95%CI 1.01−2.03]; p = 0.042), whereas the use of appropriate combination empirical treatment was independently associated with improved survival (aHR 0.46 [95%CI 0.27−0.78]; p = 0.004). Appropriate empirical monotherapy was not associated with improved overall survival (aHR 1.25 [95%CI 0.76−2.05]; p = 0.39). Combination antibiotic empirical therapy should be administered promptly in febrile neutropenic patients with suspected pneumonia as the source of infection.

Indexed as

bloodstream infectionneutropeniapneumoniaPseudomonas aeruginosaseptic shock

Identifiers

PMID35456784
PMCPMC9027680
OpenAlexW4220726895

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.